Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia

Table 1

Basic characteristics of ITP patients.

Patients	Gender	Age (year)	Platelet	Therapy	Patients	Gender	Age (year)	Platelet	Therapy	Controls	Gender	Age (year)
1	M	33	3	—	26	F	28	17	GC	1	M	22
2	F	24	24	—	27	F	22	8	GC	2	M	29
3	F	43	13	—	28	F	63	13	GC	3	F	35
4	F	64	19	—	29	F	34	38	GC, TPO	4	M	45
5	F	51	12	—	30	M	54	32	GC	5	F	59
6	F	61	33	—	31	M	58	107	GC	6	F	58
7	F	57	38	—	32	M	31	42	DNZ	7	M	44
8	F	43	34	—	33	F	40	121	GC, DNZ	8	M	42
9	M	48	9	—	34	F	51	18	DNZ	9	M	28
10	F	54	25	—	35	F	68	34	GC	10	F	20
11	M	76	22	—	36	M	45	160	GC	11	M	62
12	F	51	16	—	37	F	69	25	GC, DNZ	12	F	34
13	F	28	1	—	38	F	26	109	GC, DNZ	13	F	27
14	M	38	6	—	39	F	53	17	GC	14	F	36
15	M	45	6	—	40	F	26	123	GC	15	F	45
16	M	48	2	—	41	F	35	3	GC	16	M	46
17	M	63	25	—	42	M	23	35	GC, IVIg	17	F	51
18	F	54	44	—	43	M	46	113	GC, IVIg	18	F	22
19	F	27	35	—	44	M	22	24	GC	19	F	35
20	F	44	46	—	45	M	50	116	GC, DNZ	20	M	37
21	F	35	13	—	46	M	74	48	GC	21	M	40
22	F	28	18	—	47	M	50	38	GC	22	F	63
23	F	36	40	—	48	M	53	46	GC	23	F	65
24	M	33	43	—	49	M	27	3	GC	24	M	33
25	F	63	10	—	50	M	40	15	GC	25	M	28

M: male; F: female; GC: hormone; TPO: thrombopoietin; DNZ: danazol; IVIg: intravenous immunoglobulin.